18 ingredients set for OTC switch in Japan, including PPIs
Japan\'s Ministry of Health, Labor and Welfare revealed 18 active ingredients that may be shifted from prescription-only status to over-the-counter. The Ministry asked the Japan Association of Medical Sciences and its 107 affiliate medical societies to discuss the pros and cons of the move based on a report about the switch candidates compiled by the Pharmaceutical Society of Japan, to which the MHLW had delegated the task.
Among the 18 ingredients, are omeprazole, rabeprazole and lansoprazole (proton pump inhibitors) for gastric ulcer, ofloxacin and norfloxacin (new quinolone antiviral eyedrops) for infection, colestimide (cholesterol absorption inhibitor) for the treatment of hyperlipidemia, clobetasone butyrate (adrenal cortical steroid) and alfacalcidol and calcitriol (vitamin D3 preparations) for osteoporosis.
The Subcommittee on Non-prescription Drugs within the Council for Pharmaceutical Affairs and Food Sanitary intends to discuss the matter after soliciting views from the medical associations by July 17.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze